Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
May 7, 2019 Off

Gaurav Sharma Joins as Therapeutic Area Leader, Rare Disease and Oncology

By BusinessWire

Expands Worldwide Clinical Trials’ Oncology Franchise MORRISVILLE, N.C.–(BUSINESS WIRE)–Worldwide Clinical Trials, Inc., (Worldwide) an award-winning, full-service, midsize, global CRO, announced…

May 7, 2019 Off

CLSA Selects Zuman as Exclusive Provider of HR, Payroll and Benefits Administration Services within CLSA’s Member2Member Program

By BusinessWire

Zuman to offer price discounts to CLSA Members generally and to those joining the CLSA Benefits Advantage Trust PLEASANTON, Calif.…

May 7, 2019 Off

Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China

By BusinessWire

CHENGDU, China–(BUSINESS WIRE)–Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced it has received…

May 7, 2019 Off

Advaxis to Participate in Five Upcoming Industry Conferences

By BusinessWire

PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces…

May 7, 2019 Off

Engitix Ltd Appoints Gino Van Heeke as Chief Scientific Officer

By BusinessWire

LONDON–(BUSINESS WIRE)–Engitix Ltd, a company pioneering the development of both tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and…

May 7, 2019 Off

New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers

By BusinessWire

SY-1365 Currently in Phase 1 Clinical Trial in Relapsed and Treatment-Resistant Ovarian and Breast Cancer Patients CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals…

May 7, 2019 Off

Sensei Biotherapeutics Announces Clinical Trial Collaboration Agreement with AstraZeneca for Two Phase 2 Studies of SNS-301

By BusinessWire

Trials to Evaluate the Safety, Tolerability and Preliminary Activity of Sensei’s SNS-301, in Combination with IMFINZI® (durvalumab), in Multiple Solid…

May 7, 2019 Off

Mati Therapeutics Phase II Nepafenac Evolute® Clinical Trial Results Show Significant Post-Operative Pain Reduction in Cataract Surgery Patients

By BusinessWire

Positive Results Seen for Both Pain and Inflammation AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics Inc. (“Mati”) announced that it has completed a…

May 7, 2019 Off

Clovis Oncology Announces First Quarter 2019 Operating Results

By BusinessWire

$33.1M in Rubraca® (rucaparib) global sales for the first quarter of 2018 Updated data on 52 patients with BRCA-mutant mCRPC…

May 7, 2019 Off

Kyn Therapeutics Strengthens Leadership Team with Key Appointments

By BusinessWire

BOSTON–(BUSINESS WIRE)–Kyn Therapeutics, a clinical-stage biotechnology company developing highly differentiated cancer immunotherapies, today announced the appointment of Jeffrey Ecsedy, Ph.D.,…

Posts pagination

Previous 1 … 3,218 3,219 3,220 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine